Successful treatment of comorbid obsessive-compulsive disorder with aripiprazole in three patients with bipolar disorder

General Hospital Psychiatry

Volumn 32, Issue 5, 2010, Pages 556-558

  Uguz, Faruk ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

Aripiprazole; Bipolar disorder; Obsessive compulsive disorder

Indexed keywords

ARIPIPRAZOLE; LITHIUM SALT; OLANZAPINE; PAROXETINE; VALPROIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BIPOLAR DISORDER; CASE REPORT; COMORBIDITY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; HYPOMANIA; MALE; MANIA; OBSESSIVE COMPULSIVE DISORDER; PSYCHOLOGICAL RATING SCALE; REMISSION; SCORING SYSTEM; SYMPTOM; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COMORBIDITY; FEMALE; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUINOLONES; TREATMENT OUTCOME; TURKEY; YOUNG ADULT;

EID: 77956870458     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2010.07.004     Document Type: Article

References (19)

1. Kivircik Akdede B.B., Alptekin K., Akvardar Y., Kitiş A. Quality of life in patients with obsessive-compulsive disorder: relations with cognitive functions and clinical symptoms. Turk Psikiyat Derg 2005, 16:13-19. (in Turkish).
2. Bobes J., González M.P., Bascarán M.T., Arango C., Sáiz P.A., Bousoño M. Quality of life and disability in patients with obsessive-compulsive disorder. Eur Psychiatry 2001, 16:239-245.
3. Simon N.M., Otto M.W., Wisniewski S.R., Fossey M., Sagduyu K., Frank E., et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2004, 161:2222-2229.
4. McElroy S.L., Altshuler L.L., Suppes T., Keck P.E., Frye M.A., Denicoff K.D., et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001, 158:420-426.
5. Tamam L., Ozpoyraz N. Comorbidity of anxiety disorder among patients with bipolar disorder in remission. Psychopathology 2002, 35:203-209.
6. Koyuncu A., Tükel R., Özyildirim I., Meteris H., Yazici O. Impact of obsessive-compulsive disorder comorbidity on the sociodemographic and clinical features of patients with bipolar disorder. Compr Psychiatry 2010, 51:293-297.
7. Joshi G., Mick E., Wozniak J., Geller D., Park J., Strauss S., et al. Impact of obsessive-compulsive disorder on the antimanic response to olanzapine therapy in youth with bipolar disorder. Bipolar Disord 2010, 12:196-204.
8. Hirose T., Uwahodo Y., Yamada S., Miwa T., Kikuchi T., Kitagawa H., et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 2004, 18:375-383.
9. Arbaizar B., Dierssen-Sotos T., Gómez-Acebo I., Llorca J. Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. Gen Hosp Psychiatry 2009, 31:478-483.
10. McIntyre R.S. Aripiprazole fort he maintenance treatment of bipolar I disorder: a review. Clin Ther 2010, 32(Suppl A):S32-S38.
11. Glick I.D., Poyurovsky M., Ivanova O., Koran L.M. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms. An open-label study of 15 patients. J Clin Psychiatry 2008, 69:1856-1859.
12. Pessina E., Albert U., Bogetto F., Maina G. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol 2009, 24:265-269.
13. Fornaro M., Gabrielli F., Vinciguerra V., Fornaro P. Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report. Ann Gen Psychiatry 2008, 7:26.
14. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Clinical Version (SCID-I/CV) 1997, American Psychiatric Press, Washington, DC.
15. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., et al. The Yale-Brown Obsessive Compulsive Scale: I. Development, use and reliability. Arch Gen Psychiatry 1989, 46:1006-1011.
16. Connor K.M., Payne V.M., Gadde K.M., Zhang W., Davidson J.R. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 2005, 66:49-51.
17. Raja M., Azzoni A. Clinical management of obsessive-compulsive bipolar comorbidity: a case series. Bipolar Disord 2004, 6:164-170.
18. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L., Sibley D.R., et al. Aripiprazole, a novel atypical antipsychotic drug wit a unique and robust pharmacology. Neuropsychopharmacology 2003, 28:1400-1411.
19. Skapinakis P., Papatheodorou T., et al. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 2007, 17:79-93.